The service
Oncology competitive intelligence, delivered as a service.
A standing intelligence function for your pipeline — not a database to mine, not a deck that arrives once. One analyst reads every source and tells you what to do about it.
Oncology competitive intelligence is the practice of knowing, continuously, what every competitor in your space is doing to the value of your asset — and what to do about it while there is still time to act. Big pharma runs it as an internal department. Everyone else buys a six-figure database and hopes someone has time to mine it.
Prognyx is the third option: the function itself, outsourced, priced for a company with one lead asset and no CI team.
Who this is for
Prognyx fits a specific shape of company, and says so plainly because a bad fit wastes both our time:
- Clinical-stage oncology biotechs, typically Series B and later or newly listed, with one or two assets that carry the company's value.
- No internal CI function — the work currently lands on a CBO, a head of BD, or a CMO who is doing it at 11pm on top of their real job.
- A real competitive threat with a date on it: a rival readout, a PDUFA, a congress presentation, a filing window.
- Oncology. Only oncology. A generalist watching twelve therapeutic areas cannot tell you what a hazard ratio of 0.76 with no p-value means for your filing strategy.
It is a poor fit if you already run a staffed CI team with platform subscriptions — in that case you need tooling to make your analysts faster, not another analyst. And it is a poor fit if you need coverage across many therapeutic areas.
What you get
A scoped competitive set
We map your targets, mechanisms, indications and the specific rival assets that can move your value — agreed in writing before the watch starts, revisited as your programme moves.
Continuous watch
Registries, FDA and EMA actions, SEC filings, publications and congress abstracts, monitored between deliverables. The watch does not pause because a brief just shipped.
Briefs when it matters
A competitor move becomes a brief on your desk inside 72 hours — what happened, what it means for you, who is exposed, what to watch and the two or three moves actually on the table.
Answers on demand
Between briefs, you can ask. "Did anyone present on this target at ESMO?" gets a sourced answer, not a queue ticket.
Everything traced
Every factual claim links to the primary record — NCT number, filing, label, abstract. You can verify the whole brief without taking a word on trust.
Briefs people read
Written to be forwarded to a board or a co-founder without a translation layer. An intelligence deliverable nobody reads is a cost, not an asset.
Why not a data platform
Enterprise CI platforms — Cortellis, Citeline, Evaluate, GlobalData, AlphaSense — are genuinely good at what they are for: breadth of coverage, structured data, and giving a trained analyst a place to work. They are the right purchase when you have analysts.
The mismatch for a single-asset biotech is not quality, it is shape. A platform sells you access and leaves the analysis to you; the cost that actually hurts is not the licence fee but the senior hours spent mining it. And the licence fee is designed for a company with a CI department to amortise it across.
If you are actively comparing, the honest side-by-side is here: Prognyx vs Cortellis and Prognyx vs AlphaSense — including what each does better than Prognyx.
Why not a consulting project
A boutique CI consultancy will produce an excellent landscape assessment, once, for somewhere in the region of a mid-five-figure project fee. It is the right purchase for a discrete strategic question with a decision date — a licensing evaluation, a go/no-go.
It is the wrong shape for competitive dynamics, because competitive dynamics do not hold still for the six weeks between scoping and delivery. A landscape deck is accurate on the day it lands and decaying by the following quarter. Prognyx is built as a standing watch precisely because the value is in continuity, not in depth-at-one-moment.
Why not do it in-house
Plenty of companies do, and for the first while it works: your CSO knows the field better than any outside analyst and can hold the important twenty trials in her head. The failure mode is not competence, it is attention. The watch is the first thing dropped when a manufacturing issue or a financing lands, and it is dropped silently — you don't find out the watch lapsed until the competitor's abstract is already public.
The realistic comparison is not Prognyx versus a full-time analyst hire. It is Prognyx versus the version of this work that currently happens on nights and weekends, inconsistently.
What it costs
Month to month · no lock-in · no seat minimum
From $2,000 / month
A monthly retainer, scoped to your pipeline: continuous watch across your targets, mechanisms and indications, plus the briefs that come out of it. That is a fraction of an enterprise platform, where CI subscriptions run into the tens of thousands of dollars a year and up.
Every named competitor in this category hides pricing. Prognyx publishes it because the buyers this service is built for — companies with one asset and a real budget constraint — are exactly the people who will not send an email to discover a number.
How an engagement starts
- A free sample brief. Name one asset you'd want watched. You get a real competitive brief on it, built the same way a client's is, at no cost and with no obligation. This is the whole evaluation step — read the work before discussing money.
- A scoping conversation. Thirty minutes on your competitive set: which rivals, which mechanisms, which dates matter. Public information is enough; unpublished results are not needed.
- A pilot or a retainer. Either a one-off pilot brief, or the continuous watch from month one. Most people start with the pilot, and that is the sensible order.
There is no procurement process, no seat minimum and no annual lock-in to negotiate out of. It is one person; the engagement is a written scope and a monthly invoice.
What Prognyx is not
It is not a platform, not a dashboard, and not a login. It is not medical or investment advice — see terms. It is not a generalist CI shop that also covers oncology. And it is not anonymous: Rali Filali writes and audits every brief and puts his name on it, which is the whole point of buying a person rather than a subscription. The procedure that keeps the work honest is published on how we work.
Frequently asked
What is competitive intelligence in pharma?
Competitive intelligence in pharma is the continuous collection and analysis of public information about rival drug programmes — clinical trials, regulatory actions, corporate disclosures, publications and congress data — to inform strategic decisions about your own asset. It is not market research and not surveillance: everything used is public. The output is a read on how a competitor's move changes your positioning, and what to do about it.
How much does outsourced competitive intelligence cost?
Prognyx retainers start at $2,000 per month, scoped to your pipeline, with one-off pilot briefs at $1,500–3,000. For comparison, enterprise CI platform subscriptions commonly run into the tens of thousands of dollars per year and boutique CI consulting projects into the mid five figures.
How is this different from a competitive intelligence platform?
A platform sells access to data and leaves the analysis to your team; it assumes you have analysts. Prognyx sells the analysis — the watch, the judgement and the "what to do" — and assumes you don't. If you have a staffed CI team, buy the platform. If the work currently lands on your CBO at 11pm, buy the function.
Which therapeutic areas does Prognyx cover?
Oncology only, and that is deliberate. Depth in one field is what makes it possible to say something useful about a specific hazard ratio, endpoint or regulatory precedent. Prognyx will decline work outside oncology rather than cover it thinly.
Do I have to share confidential data?
No. Scoping needs your assets, mechanisms and indications — normally already public in your pipeline page or filings. Prognyx does not need and does not ask for unpublished results or internal strategy documents to do the watch.
How fast is a brief after a competitor moves?
The target is 72 hours from the move to a brief on your desk. If a move cannot be verified against a primary source in that window, you are told it is unverified rather than left waiting in silence.
Can I cancel?
Yes — retainers run month to month, with no annual commitment and no notice period to argue about. The reason for making it easy to leave is that a CI retainer should have to earn renewal every month, and the ones that hide behind a contract usually stopped earning it.
Start with the work, not a sales call.
Name one asset you'd want watched. You get a real competitive brief on it — sourced, sharp, free, no obligation.
Request a sample brief → Read five published briefings